title: Improvement of sympathetic skin responses under enzyme replacement therapy in Fabry disease.
abstract: OBJECTIVE
  To report the effect of enzyme replacement therapy (ERT) in sympathetic skin responses (SSR) of patients with Fabry disease.
  
  
  METHODS
  Seven male patients were included in an open-label protocol using agalsidase-alfa, continued at regular intervals. Five patients completed 24 months of ERT and two of them completed 18 months. Two main measurements were performed at baseline, as well as 1 and 2 years after ERT: (1) a standard neurological examination (NE), with a detailed evaluation of the sensory perception of light touch, pinprick, cold, hot, and vibratory stimuli; (2) the SSR amplitudes.
  
  
  RESULTS
  Although there were no significant differences between NE in this time period, all patients reported general improvement in their subjective reports of acroparaesthesia and sweating. Before starting ERT, the SSR amplitudes were either too small (3/7 patients) or absent (4/7 patients): the average (range) amplitude of 122 microV (0 through 492) was statistically smaller than that found in a control group, i.e. 1453.6 microV (619.7-2754) (p<0.0001, t-test). Mean +/- SD SSR amplitude increased to 1088+/- 690 microV in the second year of ERT, reaching the range found in a normal control group (p=0.004).
  
  
  CONCLUSIONS
  ERT improved SSR continuously in Fabry patients in 2 years of observation. Although the mechanism of the SSR improvement is unknown, this response to ERT can be clinically significant if it reflects a normalization in sweating.
authors.affiliation: Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
authors.forename: L B
authors.initials: LB
authors.lastname: Jardim
authors.forename: I
authors.initials: I
authors.lastname: Gomes
authors.forename: C B O
authors.initials: CB
authors.lastname: Netto
authors.forename: D B
authors.initials: DB
authors.lastname: Nora
authors.forename: U S
authors.initials: US
authors.lastname: Matte
authors.forename: F
authors.initials: F
authors.lastname: Pereira
authors.forename: M G
authors.initials: MG
authors.lastname: Burin
authors.forename: L
authors.initials: L
authors.lastname: Kalakun
authors.forename: R
authors.initials: R
authors.lastname: Giugliani
authors.forename: J
authors.initials: J
authors.lastname: Becker
mesh_terms: D000367:Age Factors; D016022:Case-Control Studies; D002675:Child, Preschool; D004252:DNA Mutational Analysis; D057487:Enzyme Therapy; D000795:Fabry Disease / Q000188:drug therapy*; D006801:Humans; D007527:Isoenzymes / Q000494:pharmacology; D008297:Male; D008969:Molecular Sequence Data; D009154:Mutation; D009460:Neurologic Examination; D011994:Recombinant Proteins; D012867:Skin / Q000473:pathology*; D013997:Time Factors; D000519:alpha-Galactosidase / Q000494:pharmacology*
chemical_list: D007527:Isoenzymes; D011994:Recombinant Proteins; C000627036:agalsidase alfa; D000519:alpha-Galactosidase